“The apprehension with working with non IID detailed ingredients is justified as it can be unattainable To judge if FDA would find the ‘novel excipient’ Risk-free for use in a drug product as there's no outlined procedure for analysis and acceptance of excipients. The FDA direction on ‘Nonclinical Scientific https://josefan702gcx3.blog4youth.com/profile